[Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
Maniwa
Takashi
T
takashi-maniwa@ds-pharma.co.jp
Yamamoto
Yutaka
Y
D000666:Amphotericin B / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D001230:Aspergillus / Q000187:drug effects*; D002175:Candida / Q000187:drug effects*; D017322:Clinical Trials, Phase II as Topic; D003454:Cryptococcus / Q000187:drug effects*; D025141:Drug Resistance, Fungal; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D009503:Neutropenia / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B